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3-M syndrome is an autosomal-recessive primordial growth disorder characterized by signiﬁcant intrauterine and postnatal growth
restriction.Mutations in theCUL7 gene are known to cause 3-M syndrome. In 3-M syndrome patients that do not carry CUL7mutations,
we performed high-density genome-wide SNP mapping to identify a second locus at 2q35-q36.1. Further haplotype analysis revealed
a 1.29 Mb interval in which the underlying gene is located and we subsequently discovered seven distinct null mutations from 10 fami-
lies within the gene OBSL1. OBSL1 is a putative cytoskeletal adaptor protein that localizes to the nuclear envelope. We were also able to
demonstrate that loss of OBSL1 leads to downregulation of CUL7, implying a role for OBSL1 in the maintenance of CUL7 protein levels
and suggesting that both proteins are involved within the same molecular pathway.3-M syndrome (MIM 273750) is characterized by prenatal
growth restriction in the absence of recognizable maternal
or placental pathology and by the failure of postnatal
catch-up growth resulting in signiﬁcant proportionate
short stature. The syndrome is associatedwithdistinct facial
features (triangular face, ﬂat maxillae, and prominent fore-
head), radiological abnormalities (tall vertebrae, slender
long bones), and normal intelligence.1–3 Final adult height
is in the range of 115 to 150 cm (4 to 8 SD4).
Pathogenic mutations in the CUL7 gene (MIM 609577)
cause 3-M syndrome including truncating, nonsense, and
missense variants.4–6 The protein product CUL7 is the
most recently deﬁned member of the Cullin family and
is an integral part of the ubiquitin-proteasome pathway
acting as a structural protein in the formation of a SCF-
ROC1 complex. This consists of CUL7, SKP1, ROC1, and
FBXW8 and functions as a multisubunit E3 ligase.7
Although demonstrating that reduction or absence of
CUL7 has a major impact on growth and cell division, the
precise mechanisms by which this occurs remain unclear:
CUL7 has an N-terminal binding domain for the tumor
suppressor p53,8 and microRNA knockdown leads to inhi-
bition of cell cycle progression mediated by p53.9 CUL7
also interacts with IRS-1, a downstream component of the
signaling pathways of the insulin, IGF-I, and GH receptors.
Mouse embryonic ﬁbroblasts derived from Cul7 knockout
mice demonstrate accumulation of Irs-1, increased activa-
tion of Akt and Mapk pathways, and ultimately poor
cellular growth and senescence.10
In the present study, we describe themapping of a second
locus for 3-M syndrome at 2q35-q36.1 and the subsequent
identiﬁcation of mutations in the OBSL1 (MIM 610991)
gene that encodes OBSL1, a putative cytoskeletal adaptorThe Amprotein, suggesting that OBSL1 and CUL7 act in a common
cellular pathway.
We identiﬁed 10 probands with the 3-M syndrome
phenotype in whom direct DNA sequencing failed to
detectCUL7mutations. All of the patients were phenotypi-
cally indistinguishable from those with CUL7 mutations.
Detailed clinical phenotype and auxology were available
for eight of the patients. Clinical phenotype, growth,
and radiological features are summarized in Table 1. All
patients had a distinctive facial appearance with ante-
verted nares, ﬂeshy tipped nose, frontal bossing, and mid-
face hypoplasia (Figure 1). Prominent heels were present in
all cases. In keeping with previous reports, our patients had
low weight and height standard deviations scores (SDS)
with a relatively preserved occipitofrontal circumference
SDS. Height SDS toward the end of childhood was in the
range of 3 to 5 SDS. There were no clear differences in
phenotype between 3-M patients with OBSL1 mutations
and those previously reported with mutations in CUL7.
Two of the probands (3-M-4 and -5) were from multiple
affectedconsanguineouskindredscomprising fourandthree
affected individuals, respectively. Neither family exhibited
linkage to the CUL7 locus, indicating that 3-M syndrome
displays locus heterogeneity. We hypothesized that identiﬁ-
cationof furthercausativegenesmight shed lightona shared
biochemical pathway controllingmammalian growth.With
this inmind, we conducted whole-genome-wide autozygos-
ity mapping with 250 ng of genomic DNA with the HindIII
array from the 100KAffymetrixGeneChipHumanmapping
set. Blood samples and informed consent were obtained
from the affected individuals and unaffected relatives. This
study was approved by our institution’s research ethics
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Table 1. Clinical Findings of 3-M Syndrome Patients
Auxology
3-M ID 2 3 4 5 6 8 9a 9b
Gender F F F M M F M M
Birth weight (g) 2409 1900 NA 1920 2100 NA NA NA
Birth weight SDS 2.63 1.96 NA 3.86 3.77 NA NA NA
Age initial presentation (years) 1.4 0.2 11.7 4.5 1.0 NA 13.0 11.0
Height SDS at presentation 6.4 1.4 4.8 7.9 7.8 NA 4.6 3.3
Weight SDS at presentation 4.1 1.2 4.9 8.6 8.6 NA 1.7 1.3
OFC SDS at presentation þ2.4 þ1.9 NA 3.60 3.3 NA 0.8 þ0.9
Radiological Features
Tall vertebrae þ - þ - - þ - -
Slender long bones - þ - - þ - þ þ
Facial Features
Fleshy tipped nose þ þ þ þ þ þ þ þ
Anteverted nares þ þ þ þ þ þ þ þ
Full fleshy lips þ þ - þ - þ þ þ
Triangular face þ þ þ þ - þ þ þ
Dolicocephaly þ þ þ - þ þ þ þ
Frontal bossing þ þ þ þ þ þ þ þ
Midface hypoplasia þ þ þ þ þ þ þ þ
Long philtrum - þ - - þ þ þ þ
Pointed chin þ - þ þ þ þ þ þ
Prominent ears - þ - þ þ - þ þ
Other Clinical Features
Short neck - - þ þ þ þ þ -
Winged scapulae - - - - - - þ þ
Square shoulders - - þ þ þ - þ þ
Short thorax - þ - þ þ - þ þ
Transverse chest groove - - þ þ - - þ þ
Pectus deformity - þ þ þ þ - - -
Hyperlordosis þ þ þ þ þ - þ þ
Scoliosis - þ - - - - -
Hypermobility of joints - - - - - - - -
5th finger clinodactyly - - - þ - - þ þ
Prominent heels þ þ þ þ þ þ þ þ
Spina bifida occulta - - - - - - - -
Auxology, radiological features, and clinical phenotype in eight children with 3-M syndrome resulting from mutations in OBSL1. List of clinical features
taken from Temtamy et al.3.Genomic DNA was isolated from whole blood samples via
QIAGEN DNeasy kit. The array consists of 57,244 SNP
markers with a mean marker distance of 47.2 kb. SNP geno-
type analysis was conducted with the AutoSNPa program to
detect regions of shared homozygosity.11 The SNP genotype
call rate achieved was 98.15%.
All four affected siblings from family 3-M-4 shared
two regions of homozygosity (Chr2: 218,018,585–225,142,
689 bp and Chr14: 32,542,986–38,094,746 bp). Within
the region on chromosome 2 (2q35-q36.1), a smaller critical
region was also shared by all three affected individuals
in family 3-M-5 and a proband from a further consanguin-
eous family, 3-M-6. The reﬁned locus for 3-M syndrome
was a 5.7 Mb region ﬂanked by recombinants at 218,
018,585 bp (rs966423) and 223,752,494 bp (rs1597167)
(Figure 2A). The critical region contains 63 known and
hypothetical genes, 3 known miRNAs, and 5 known802 The American Journal of Human Genetics 84, 801–806, June 12pseudogenes.One of the 20 loci recently shown to be associ-
ated with adult height (SNP rs6724465) lies in this region
close to Indian Hedgehog (IHH [MIM 600726]), which
has been implicated in the control of human growth.12
However, direct sequencing of IHH was undertaken for
two affected probands and failed to identify a causative
mutation.
After the initial screening for mutations in genes within
the5.7Mbcritical region,haplotype analysis amongthepro-
bands homozygous for this region demonstrated a shared
haplotype between SNPs rs1516086 and rs10498071 for
families 3-M-4 and -5 as well as the affected proband from
family 3-M-6 (Figure 2B). This region extends over 1.29 Mb
(Chr2: 219,139,779–220,430,942 bp) and encodes for 43
known and hypothetical genes, 2 known miRNAs, and 4
known pseudogenes. A further family, 3-M-8, also demon-
strated autozygosity but did not share the same haplotype, 2009
Figure 1. Clinical Features of 3-M Syndrome Patients
(A) A patient from family 3-M-6 aged 10 years. The facial appearance is characterized by fleshy tipped anteverted nares, full fleshy lips,
triangular shaped face, midface hypoplasia, and prominent ears. These features become less prominent with
increasing age.
(B) The affected child from family 3-M-2 aged 10 months. Facial appearance is characterized by similar fleshy tipped anteverted nares, full
fleshy lips, triangular shaped face, and midface hypoplasia seen in 3-M-6 but also distinct frontal bossing. Both had proportionate short
stature. Prominent heels are seen in most patients and may be a useful diagnostic feature. Patient photographs and X-rays from two
brothers from family 3-M-9 have previously been reported by Temtamy et al.3.(Table 2). This suggested that the underlying mutation in
families 3-M-4, -5, and -6 would differ from the mutation
in 3-M-8.
Direct sequencing of genes in the 1.29 Mb critical region
was undertaken for two affected probands. Pathogenic
variants were identiﬁed in OBSL1, encoding the cytoskel-
etal linker protein obscurin-like 1 (Figures 2C and 2D).
TheOBSL1 gene, identiﬁed via homology searches with ob-
scurin, comprises 22 exons over a genomic regionof 25 kb13
with three splice forms which encode distinct isoforms
(termed OBSL1 A, B, and C) with molecular masses of
approximately 230, 130, and 170 kDa, respectively
(Figure 2C).13 Intronic primer pairs for each of the 22 exons
ofOBSL1weredesignedwithPrimer3 software.14Ampliﬁca-
tion of each fragmentwas conducted by standard PCR tech-
nique, and products were puriﬁed with Montage PCR ﬁlter
units (Millipore) and sequenced with Applied Biosystems
BDv3.1 on an ABI3730 automated analyzer (Applied
Biosystems). Sequences were compared to both control
genomic DNA and the published sequence (Ensembl ID
ENSG00000124006, GenBank accession # NC_000002.10)
with SeqScape software (Applied Biosystems).
In total, we identiﬁed 7 different OBSL1mutations in 18
patients from 10 families (Table 3) that are all presumptive
null mutations. The mutations were not identiﬁed in a
panel of 105 ethnically matched control samples, suggest-
ing that the sequence variants are not common polymor-
phisms. All of the mutations identiﬁed in these families
lie within the ﬁrst 6 exons of the gene and thus affect all
known isoforms.
We ﬁrst assessed whether the OBSL1mutations identiﬁed
induce nonsense-mediated decay (NMD) as predicted or
would allow illegitimate downstream translation, explain-
ing the clustering of mutations near to the N terminus
of OBSL1. OBSL1 truncating mutants were created by
PCR via an IMAGE: 2961284 cDNA clone containing theThe AmcDNA sequence that corresponds to OBSL1 isoform B (Gen-
Bank accession # BC007201). PCR products were cloned
into pcDNA3.1 (Invitrogen) creating N-V5-OBSL1, C-V5-
OBSL1,N-V5-OBSL1c.1273insA,N-V5-OBSL1c.1463C/T,
C-V5-OBSL1 c.1273insA, and C-V5-OBSL1 c.1463C / T
constructs. Each isoform was fused to a V5 tag at either
the N or C termini. Both wild-type and mutant isoforms
of a full-length human OBSL1 cDNA (c.1273insA and
c.1463C / T) were transiently expressed in HEK293
cells via Effectene transfection reagent (QIAGEN) according
to the manufacturer’s protocol. Protein expression was
analyzed by standard western blot protocol with a mono-
clonal antibody for V5 (AbD Serotec). For both mutant
isoforms, we were able to detect N-terminally tagged
proteins but unable to detect C-terminally tagged proteins
(Figure 3A). This suggested that no alternative translational
start site would be used in the event of mutations located
toward the N terminus of OBSL1. We therefore conclude
that these mutations result in the loss of OBSL1, and given
thephenotypic similarity inpatientswithOBSL1mutations,
that 3-M syndrome represents thenull phenotypeofhuman
OBSL1.
In order to assess the effects of OBSL1 loss, we knocked
it down by using two separate siRNAs in HEK293 cells
(Figure 3B). Both siRNAs were designed to target all
three isoforms of OBSL1 (Ambion) and were transfected
into HEK293 cells with siPORT Amine transfection
reagent (Ambion) according to the manufacturer’s recom-
mended protocol. 48 hr after transfection, cells were
lysed followed by analysis of protein expression by
western blot with a custom polyclonal antibody to
OBSL1 (Eurogentec) and monoclonal antibodies for
GAPDH, p53, and CUL7 (Santa-Cruz Biotechnology).
We were unable to detect either OBSL1 or CUL7, suggest-
ing a role for OBSL1 in the maintenance of normal level-
s of CUL7. In the same experiment, expression of p53erican Journal of Human Genetics 84, 801–806, June 12, 2009 803
Figure 2. Genetic Mapping of the Second 3-M Syndrome Locus
(A) The region of common autozygosity shared between 3-M families 4 and 5 is located between rs966423 and rs1597167.
(B) The identical haplotype shared between 3-M families 4–6 located between rs1516086 and rs10498071.
(C) Exon and intron structure of OBSL1 with mutations identified in 10 3-M syndrome families and domain structure of each OBSL1
isoform.
(D) Sequence traces of the OBSL1 mutations (i. families 2–7; ii. family 9) with corresponding wild-type sequences.was unchanged (Figure 3B) as has previously been shown
in Cul7/ MEFs in which p53 levels were also
unchanged.15
To our knowledge we report the ﬁrst identiﬁcation of
pathogenic sequence variants in OBSL1, a cytoskeletal
adaptor protein, causing the primordial growth disorder
3-M syndrome. OBSL1 is homologous to obscurin, which
is a muscle protein localized to sarcomeres implicated in
cell signaling. Obscurin interacts with titin andmyomesin,
proteins involved in anchoring myosin ﬁlaments at the
M-band in myocytes, and both titin and myomesin also
interact with OBSL1.16 Expression of OBSL1 has been
demonstrated in human heart and skeletal muscle,13
a ﬁnding we have conﬁrmed in the mouse, in which the
strongest expression was demonstrated at stage E11.5 in
the developing myotomes (data not shown).
OBSL1 consists entirely of immunoglobulin-like
domains and a single ﬁbronectin domain; this tertiary
structure would suggest a primary role in protein-protein
interaction. Geisler et al. postulated that this would be
to stabilize the cytoskeletal network or act as a scaffold
for signaling complexes with a proposal that disruption804 The American Journal of Human Genetics 84, 801–806, June 12of OBSL1 would cause either skeletal or cardiac myop-
athy.13 In our current investigation, however, patients
with mutations in OBSL1 were not found to have cardio-
vascular or muscular symptoms and it is possible that the
overlapping ability of both OBSL1 and obscurin to bind
titin and myomesin provides a degree of redundancy to
explain this.
All mutations occurred in the ﬁrst six exons of theOBSL1
gene. We were able to demonstrate that all mutations re-
ported do not induce nonsense-associated altered splicing
(NAS), a mechanism by which alternatively spliced mRNA
transcripts skipping the premature termination codon
(PTC) are retained.17 It is therefore likely that OBSL1muta-
tions induce the NMD pathway. The NMD pathway is the
opposite of the NAS pathway whereby mRNAs containing
a PTC are rapidly degraded.18 Therefore, the identiﬁcation
of a hot-spot is unexpected because mutations located
in any coding exon except the last would induce the
same NMD mechanism. We propose that mutations near
the N terminus lead to loss of all OBSL1 isoforms, explain-
ing the clustering of mutations in this region of the
gene; we hypothesize that 3-M syndrome represents the, 2009
Table 2. Haplotype Analysis of Consanguineous 3-M Syndrome Families
Position SNP ID Allele A Allele B 3-M-4 3-M-5 3-M-6 3-M-8
219139779 rs1516086 C T AA AA AA AA
219220550 rs10498061 A G BB BB BB BB
219228649 rs3931102 A G BB BB BB BB
219245468 rs2241527 A G AA AA AA AA
219246263 rs1344645 A C AA AA AA AA
219247043 rs7604319 G T AA AA AA AA
219309636 rs7573999 A G BB BB BB BB
219529413 rs4672907 C T BB BB BB AA
219668323 rs10498064 A T NoCall BB BB BB
219711078 rs6436114 A C BB BB BB BB
219719336 rs2293081 A C BB BB BB AA
219720820 rs7585742 C G BB BB BB AA
219757631 rs2385393 C T AA AA AA AA
219874198 rs2292607 C T BB BB BB BB
220249416 rs10498065 C T AA AA AA BB
220287516 rs714132 A T BB BB BB BB
220288529 rs2385573 A G BB BB BB AA
220288792 rs678134 C T AA AA AA AA
220368946 rs10498069 A G BB BB BB BB
220380412 rs2113855 C T BB BB BB BB
220430942 rs10498071 C T AA AA AA AA
Haplotype analysis with identical genotypes in 3-M-4, -5, and -6 between rs1516086 and rs10498071, with 3-M-8 having an alternative haplotype.null phenotype. The occurrence of a common mutation
(p.T425NfsX40) in a large number of families from the
same ethnic (Asian) background suggests that this may
be a founder mutation, an observation supported by SNP
analyses. Additionally, we have identiﬁed consanguineous
families with 3-M syndrome who have neither CUL7
nor OBSL1 mutations and who are not linked to either
genomic region, indicating that there is at least one further
locus causing this growth disorder.
Because pathogenic CUL7 mutations also cause 3-M
syndrome, we proposed that OBSL1 acts within the same
pathway as CUL7 or is involved in trafﬁcking of the CUL7
SCF complex, a suggestion supported by the observation
that knockdown of OBSL1 via siRNAs in HEK cells leads to
concomitant knockdown of CUL7. Thus we suggest that
loss of CUL7 either throughmutations in CUL7 or through
loss of OBSL1 may lead to a decrease in cell proliferation
Table 3. Mutations Identified in OBSL1
3-M ID Nucleotide Change Protein Change
1 c.690insC p.E231RfsX23










9 c.1463C/ T p.R489X
10 c.2034_2035 delinsA p.H679TfsX40
OBSL1 mutations identified in 10 families with 3-M syndrome. Where
a single mutation is listed, patients are homozygous for that mutation.The Amresulting in the 3-M syndrome phenotype. This therefore
implicates two hitherto unrelated cytoplasmic proteins
in the pathogenesis of the human growth disorder 3-M
syndrome, one a ubiquitin ligase (CUL7) and the other
a cytoskeletal adaptor (OBSL1). The identiﬁcation of the
ubiquitinated target of the CUL7 SCF complex will likely
further enhance our understanding of how defects in
CUL7/OBSL1 pathway cause pre- and postnatal growth
restriction. The characterization of disorders associated
Figure 3. OBSL1 Mutations Induce NMD and siRNA Knockdown
of OBSL1 Results in Decreased CUL7 Expression
(A) Western blot analysis of V5-tagged OBSL1 clones. Expression of
N- or C-terminally tagged OBSL1 isoforms in HEK293 cells led to the
detection of N-tagged isoforms (lanes 1 and 2) but not of C-tagged
isoforms (lanes 3 and 4), demonstrating the expression of prema-
turely truncated isoforms. Wild-type protein tagged at either
terminus was detected (lanes 5 and 6).
(B) siRNA knockdown of OBSL1 in HEK293 cells via two different
siRNAs (that target all three wild-type isoforms) resulted in the
decreased expression of CUL7 (second from top, upper band
[arrow], lower band represents nonspecific binding) but did not
alter the expression of p53 (third from top). The bottom gel shows
a GAPDH loading control.erican Journal of Human Genetics 84, 801–806, June 12, 2009 805
with signiﬁcant pre- and postnatal growth retardation
can allow identiﬁcation of potential human growth regula-
tors as demonstrated recently by the studies of primordial
dwarﬁsm (microcephalic osteodysplastic primordial
dwarﬁsm type II [MIM 210720]), demonstrating the impor-
tance to human growth of themitotic spindle in regulating
normal chromosome segregation.19 We now demonstrate
that the CUL7/OBSL1 pathway is also a key contributor to
the regulation of human growth.
Supplemental Data
Supplemental Data include two tables and can be found with this
article online at http://www.ajhg.org/.
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